Lucid Capital analyst Elemer Piros initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $8 price target The company is developing chronic steroid treatments for rare diseases with “blockbuster potential,” the analyst tells investors in a research note. The firm believes the company’s EryDex is set to become a blockbuster treatment in the lead ataxia-telangiectasia indication alone.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX: